18-MC (18-Methoxycoronaridine): What Animal Studies Show—and Why It Is Not Ibogaine

Definition

Definition: This article summarizes preclinical addiction literature on 18-methoxycoronaridine (18-MC; developmental names include MM-110 / zolunicant)—a synthetic iboga alkaloid congener developed to retain anti-addictive signals in animal models while reducing ibogaine-like cerebellar toxicity and tremor. Classic comparative work includes **Glick S.D. et al., “18-Methoxycoronaridine (18-MC) and Ibogaine: Comparison of Antiaddictive Efficacy, Toxicity, and Mechanisms of Action,” *Annals of the New York Academy of Sciences* (2000; doi: 10.1111/j.1749-6632.2000.tb05211.x)**, and earlier CNS Drug Reviews framing (Glick/Maisonneuve/Kuehne lineage). Modern medicinal-chemistry context appears in reviews such as Pace et al., *Journal of Medicinal Chemistry* (2022; doi: 10.1021/acs.jmedchem.2c01562) on α3β4 nicotinic acetylcholine receptor inhibitors inspired by ibogaine. Preclinical (animal) research. Animal self-administration reductions are not human IV ibogaine proof, not regulatory approval, and not a consumer “safer ibogaine pill” claim. Human Phase 1 work on MM-110 was reported by developers; active commercial development has been halted/reprioritized historically—still not an approved therapy. Ibogaine itself remains U.S. Schedule I and not approved for any indication. QTc risk for ibogaine parent remains clinically central.

Short answer

18-MC (18-methoxycoronaridine) is a preclinical ibogaine congener that reduced drug self-administration in rodent models with less cerebellar toxicity than high-dose ibogaine in comparative studies. Preclinical analog data are not human psychoactive IV ibogaine infusion proof and not an approved cure. Schedule I parent compound; demand cardiac screening for any ibogaine discussion.

Why this paper matters

Analog hype (“scientists invented safe ibogaine”) floods search results. This article keeps 18-MC labeled preclinical, separates it from tabernanthalog (/blog/cameron-2020-tabernanthalog), and blocks route laundering into claims about IV ibogaine infusion. Next steps: /safety-and-screening → /apply. Pair with hERG mechanism (/blog/alper-herg-ibogaine-cardiac-mechanism)—Alper 2016 noted much weaker functional hERG block for 18-MC vs ibogaine/noribogaine in that report—and Corkery’s forward look mentioning 18-MC (/blog/corkery-ibogaine-fatalities).

What the preclinical literature claims (accurately)

Methods (plain language)

Researchers give rodents 18-MC and measure whether they self-administer opioids, stimulants, alcohol, or nicotine less. Separate histology/behavior assays ask whether tremor or Purkinje injury seen with high-dose ibogaine appears. Those experiments inform drug discovery—they do not enroll your uncle in a clinic.

Key preclinical findings (no hype)

• 18-MC reduced self-administration across multiple drug classes in rat models at doses used in the Glick comparative program.
• Unlike ibogaine in those comparisons, 18-MC did not suppress responding for water as a nondrug reinforcer in the same acute way—suggesting a cleaner behavioral profile in that assay.
• Both compounds can ameliorate some opioid withdrawal signs in animals; shared and divergent dopamine/serotonin microdialysis patterns are discussed in the classic papers.
• Structure–activity work positions α3β4 inhibition in habenula/IPN circuitry as a mechanistic hypothesis for anti-addictive effects.
• Weaker functional hERG block relative to ibogaine/noribogaine in Alper 2016 is often cited as a cardiac-SAR rationale—still not a human cardiac-safety free pass without trials.

Honest reading: Better therapeutic index *in rats* is a research hope, not a pharmacy shelf reality.

Human development status (keep humble)

Public development history includes a Phase 1 healthy-volunteer program under the MM-110 name with later sponsor reprioritization/halt of active opioid-withdrawal development. Websites must not imply patients can presently obtain approved 18-MC for OUD. Nor is halted/paused development proof that the drug “doesn’t work”—it is a capital/regulatory/strategic fact, not a consumer product launch.

Preclinical evidence only

Route honesty & entity clarity

18-MC papers are about a different molecule. They cannot validate physician-supervised psychoactive IV ibogaine infusion. Oral ibogaine clinical literature remains a separate evidence silo (/blog/ibogaine-oral-vs-iv; /what-is-ibogaine-infusion).

Link to Purkinje toxicity article

Ibogaine’s high-dose rat Purkinje degeneration is a major reason analogs were pursued (/blog/ibogaine-purkinje-cerebellar-toxicity). 18-MC’s comparative lack of that lesion class in classic studies is precisely the SAR story—still preclinical.

Cardiac safety context for the parent drug

Even when discussing “safer analogs,” remind readers that ibogaine/noribogaine remain QT-liable in human observational and mechanistic data (/blog/knuijver-2021-ibogaine-qtc-safety, /blog/alper-herg-ibogaine-cardiac-mechanism). Analog optimism is not a screening waiver.

Limits

What this does NOT prove for IV ibogaine infusion

Next steps

Curious about “safer ibogaine”? Start with real-world cardiac screening for any live ibogaine conversation: /safety-and-screening → /apply for supervised IV ibogaine infusion questions.

FAQ

What is 18-MC? 18-methoxycoronaridine—a synthetic ibogaine congener studied mainly in animals for anti-addictive effects.

Is 18-MC the same as ibogaine? No. Related structure; different pharmacology/toxicity profile in preclinical comparisons.

Is this human efficacy proof? **No—this is animal research only.**

Does it prove psychoactive IV ibogaine infusion? No.

Was there human testing? Limited early clinical development (e.g., MM-110 Phase 1 reporting) occurred; that is not regulatory approval for OUD treatment.

Why do people say it is safer? Classic rodent comparisons showed less tremor/cerebellar toxicity than high-dose ibogaine—still not a guaranteed human safety card.

Is ibogaine approved for medical use? No. Schedule I.

Where should screening start? /safety-and-screening, then /apply if appropriate.

Sources (selected)

1. Glick S.D. et al. 18-MC and Ibogaine: Comparison… *Ann NY Acad Sci*. 2000. doi: 10.1111/j.1749-6632.2000.tb05211.x.
2. Glick S.D. et al. (±)-18-Methoxycoronaridine… *CNS Drug Rev*. 1999;5:27–42. doi: 10.1111/j.1527-3458.1999.tb00084.x.
3. Pace C.J. et al. What We Have Gained from Ibogaine… *J Med Chem*. 2022. doi: 10.1021/acs.jmedchem.2c01562.
4. Alper K. et al. hERG Blockade by Iboga Alkaloids. *Cardiovasc Toxicol*. 2016. doi: 10.1007/s12012-015-9311-5.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not approved for any indication. Our IV ibogaine programs in Mexico and Gabon are not approved U.S. clinics. Next steps: /safety-and-screening, then /apply.

18-MC literature is PRECLINICAL (and early development at most)—not an approved cure and not psychoactive IV ibogaine efficacy proof.